Novel molecular targets for the therapy of urothelial carcinoma

Bagi R P Jana, Matthew D. Galsky, Noah Hahn, Matthew I. Milowsky, Guru Sonpavde

Research output: Contribution to journalArticle

Abstract

Introduction: First-line platinum-based combinations are active in locally advanced and metastatic urothelial carcinoma; however, long-term outcomes including disease-specific and overall survival remain suboptimal. In addition, approximately 40 50% of patients with advanced urothelial carcinoma have coexisting medical issues that preclude the use of cisplatin-based therapy. Improvements in our understanding of the molecular mechanisms of urothelial tumorigenesis have led to first-generation clinical trials evaluating novel agents targeting molecular pathways. These are particularly relevant in regard to subpopulations. Novel trial designs warrant consideration to accelerate accrual. Areas covered: In this review, novel molecular targets for the therapy of urothelial carcinoma, as well as recently completed and ongoing clinical trials utilizing novel targeted agents, are discussed. A Medline search with key words, abstracts reported at national conferences on urothelial carcinoma and NCI clinical trial identifiers was used for this review. Expert opinion: Improved understanding of molecular biology has identified a number of new molecular targets, but there is a seeming absence of one dominant molecular driver for urothelial cancer. An adaptive and biomarker-derived strategy may be warranted. Clinical trials utilizing targeted agents are ongoing and results are awaited.

Original languageEnglish (US)
Pages (from-to)499-513
Number of pages15
JournalExpert Opinion on Therapeutic Targets
Volume16
Issue number5
DOIs
StatePublished - May 2012
Externally publishedYes

Fingerprint

Clinical Trials
Carcinoma
Molecular biology
Biomarkers
Platinum
Cisplatin
Expert Testimony
Therapeutics
Molecular Biology
Carcinogenesis
Survival
Neoplasms

Keywords

  • Novel molecular targets
  • Targeted therapy
  • Transitional cell carcinoma
  • Urothelial carcinoma

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Novel molecular targets for the therapy of urothelial carcinoma. / Jana, Bagi R P; Galsky, Matthew D.; Hahn, Noah; Milowsky, Matthew I.; Sonpavde, Guru.

In: Expert Opinion on Therapeutic Targets, Vol. 16, No. 5, 05.2012, p. 499-513.

Research output: Contribution to journalArticle

Jana, Bagi R P ; Galsky, Matthew D. ; Hahn, Noah ; Milowsky, Matthew I. ; Sonpavde, Guru. / Novel molecular targets for the therapy of urothelial carcinoma. In: Expert Opinion on Therapeutic Targets. 2012 ; Vol. 16, No. 5. pp. 499-513.
@article{14c68a123d3a405eb5191e274ef48f2c,
title = "Novel molecular targets for the therapy of urothelial carcinoma",
abstract = "Introduction: First-line platinum-based combinations are active in locally advanced and metastatic urothelial carcinoma; however, long-term outcomes including disease-specific and overall survival remain suboptimal. In addition, approximately 40 50{\%} of patients with advanced urothelial carcinoma have coexisting medical issues that preclude the use of cisplatin-based therapy. Improvements in our understanding of the molecular mechanisms of urothelial tumorigenesis have led to first-generation clinical trials evaluating novel agents targeting molecular pathways. These are particularly relevant in regard to subpopulations. Novel trial designs warrant consideration to accelerate accrual. Areas covered: In this review, novel molecular targets for the therapy of urothelial carcinoma, as well as recently completed and ongoing clinical trials utilizing novel targeted agents, are discussed. A Medline search with key words, abstracts reported at national conferences on urothelial carcinoma and NCI clinical trial identifiers was used for this review. Expert opinion: Improved understanding of molecular biology has identified a number of new molecular targets, but there is a seeming absence of one dominant molecular driver for urothelial cancer. An adaptive and biomarker-derived strategy may be warranted. Clinical trials utilizing targeted agents are ongoing and results are awaited.",
keywords = "Novel molecular targets, Targeted therapy, Transitional cell carcinoma, Urothelial carcinoma",
author = "Jana, {Bagi R P} and Galsky, {Matthew D.} and Noah Hahn and Milowsky, {Matthew I.} and Guru Sonpavde",
year = "2012",
month = "5",
doi = "10.1517/14728222.2012.677441",
language = "English (US)",
volume = "16",
pages = "499--513",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Novel molecular targets for the therapy of urothelial carcinoma

AU - Jana, Bagi R P

AU - Galsky, Matthew D.

AU - Hahn, Noah

AU - Milowsky, Matthew I.

AU - Sonpavde, Guru

PY - 2012/5

Y1 - 2012/5

N2 - Introduction: First-line platinum-based combinations are active in locally advanced and metastatic urothelial carcinoma; however, long-term outcomes including disease-specific and overall survival remain suboptimal. In addition, approximately 40 50% of patients with advanced urothelial carcinoma have coexisting medical issues that preclude the use of cisplatin-based therapy. Improvements in our understanding of the molecular mechanisms of urothelial tumorigenesis have led to first-generation clinical trials evaluating novel agents targeting molecular pathways. These are particularly relevant in regard to subpopulations. Novel trial designs warrant consideration to accelerate accrual. Areas covered: In this review, novel molecular targets for the therapy of urothelial carcinoma, as well as recently completed and ongoing clinical trials utilizing novel targeted agents, are discussed. A Medline search with key words, abstracts reported at national conferences on urothelial carcinoma and NCI clinical trial identifiers was used for this review. Expert opinion: Improved understanding of molecular biology has identified a number of new molecular targets, but there is a seeming absence of one dominant molecular driver for urothelial cancer. An adaptive and biomarker-derived strategy may be warranted. Clinical trials utilizing targeted agents are ongoing and results are awaited.

AB - Introduction: First-line platinum-based combinations are active in locally advanced and metastatic urothelial carcinoma; however, long-term outcomes including disease-specific and overall survival remain suboptimal. In addition, approximately 40 50% of patients with advanced urothelial carcinoma have coexisting medical issues that preclude the use of cisplatin-based therapy. Improvements in our understanding of the molecular mechanisms of urothelial tumorigenesis have led to first-generation clinical trials evaluating novel agents targeting molecular pathways. These are particularly relevant in regard to subpopulations. Novel trial designs warrant consideration to accelerate accrual. Areas covered: In this review, novel molecular targets for the therapy of urothelial carcinoma, as well as recently completed and ongoing clinical trials utilizing novel targeted agents, are discussed. A Medline search with key words, abstracts reported at national conferences on urothelial carcinoma and NCI clinical trial identifiers was used for this review. Expert opinion: Improved understanding of molecular biology has identified a number of new molecular targets, but there is a seeming absence of one dominant molecular driver for urothelial cancer. An adaptive and biomarker-derived strategy may be warranted. Clinical trials utilizing targeted agents are ongoing and results are awaited.

KW - Novel molecular targets

KW - Targeted therapy

KW - Transitional cell carcinoma

KW - Urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84860254010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860254010&partnerID=8YFLogxK

U2 - 10.1517/14728222.2012.677441

DO - 10.1517/14728222.2012.677441

M3 - Article

C2 - 22510032

AN - SCOPUS:84860254010

VL - 16

SP - 499

EP - 513

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 5

ER -